A Primary Care, EHR- Based Strategy to Promote Safe & Appropriate Drug Use

Status Completed

Clinical Trial Summary

This study seeks to evaluate a low-literacy strategy in a primary health care setting for promoting safe and effective prescription medication use among English and Spanish-speaking patients with diabetes.

The investigators hypothesize that in comparison with patients receiving standard care, the patients that received the Electronic Health Record (EHR) strategy will 1) demonstrate better understanding of how to safely dose out their medication regimen; 2) have fewer discrepancies in their medication lists; 3) take their medication regimen more efficiently; 4) have greater adherence to their medication regimen.

Clinical Trial Description

The strategy takes advantage of health information technology to assist patients with Medication Therapy Management (MTM) tasks, intervening with a set of low-literacy MTM printed tools triggered by the Electronic Health Record (EHR) in a primary health care clinic. Patients at the University of Illinois at Chicago (UIC) Medicine Clinic who are randomized to the intervention arm will be given three printed tools, one when they check in to the clinic and the other two when they check out. The Electronic Health Record (EHR) triggers the printing of these tools, and the receptionist hands them to the patient. Patients receive either English or Spanish language materials depending on the preference determined in the screening process and stored in their EHR.

Specific Aims

1. Refine and Field Test an EHR strategy for generating and distributing low literacy prescription information for English and Spanish-speaking patients

2. Assess the process of the EHR intervention and its fidelity for providing prescription information for patients at the point of prescribing and dispensing medications.

3. Evaluate the effectiveness of the EHR strategy to improve medication understanding, reconciliation, regimen consolidation, and adherence compared to standard care.

In addition, we will be powered to also investigate our strategy's impact on intermediary clinical outcomes including systolic blood pressure, HbA1c, and LDL cholesterol. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01669473
Study type	Interventional
Source	Northwestern University
Contact
Status	Completed
Phase	N/A
Start date	June 2013
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT02261545` - The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient	Phase 4
Completed	`NCT02028091` - Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements	N/A
Completed	`NCT01684813` - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel	Phase 4
Completed	`NCT01252524` - Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study	N/A
Recruiting	`NCT01311401` - Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel	N/A
Completed	`NCT00563225` - 20 Week Bridging Study in Type II DM	Phase 3
Recruiting	`NCT01565096` - Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy	Phase 4
Completed	`NCT00151697` - LANN-study: Lantus, Amaryl, Novorapid, Novomix Study	Phase 3
Withdrawn	`NCT01453751` - Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes	N/A
Not yet recruiting	`NCT01775059` - Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4	N/A
Completed	`NCT01281098` - Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.	Phase 2
Completed	`NCT02036372` - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus	N/A
Completed	`NCT03258840` - EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus	N/A
Active, not recruiting	`NCT01386801` - Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana	N/A
Completed	`NCT02144948` - Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms